论文部分内容阅读
目的:观察原发性高血压(EH)不同合并症患者体内炎症反应的程度与中药血脂康的干预疗效。方法:观察EH患者120例,根据其合并症的不同,分为单纯EH组30例,EH合并心房颤动(EH-AF)组30例,EH合并腔隙性脑梗死(EH-LI)组30例,EH合并左心室肥厚(EH-LVH)组30例,同时选择30例健康体检者作为对照组。每组EH患者随机又分为两个亚组,即常规治疗亚组(主要运用钙拮抗剂ACEI、ARB、利尿剂、β受体阻断剂等药物治疗8周)和血脂康干预亚组(常规治疗加血脂康1.2g/d)。药物治疗前后检测血hs-CRP、IL-6水平。结果:(1)所有入选EH患者的hs-CRP、IL-6水平显著高于正常对照组(P<0.05);(2)EH-AF组、EH-LI组、EH-LVH组的hs-CRP、IL-6水平无明显差异(P>0.05),但均显著高于单纯EH组(P<0.05);(3)血脂康组和常规治疗组治疗后,其hs-CRP、IL-6水平均显著下降(P<0.05),两组间比较,血脂康组明显更优(P<0.05);(4)血脂康组和常规治疗组治疗后,其血压均显著下降(P<0.05),两组间比较,血脂康组的血压下降幅度更加显著(P<0.05)。结论:炎症反应指标hs-CRP、IL-6的上升与EH并发症的产生关系密切,血脂康能够显著下调EH患者的hs-CRP、IL-6和血压水平,提示联合应用降压药物和血脂康对于EH患者可能更为有益。
Objective: To observe the degree of inflammatory reaction in patients with different comorbidities of essential hypertension (EH) and the intervention effect of Xuezhikang. Methods: One hundred and twenty patients with EH were enrolled in this study. According to their complications, they were divided into EH group (30 cases), EH combined atrial fibrillation group (EH-LI group) and EH combined with lacunar infarction Cases, EH with left ventricular hypertrophy (EH-LVH) group of 30 patients, while 30 healthy subjects were selected as the control group. Each group of EH patients were randomly divided into two subgroups, namely, the routine treatment subgroup (mainly using calcium antagonists ACEI, ARB, diuretics, β-blockers and other drugs for 8 weeks) and the intervention group Xuezhikang Routine treatment plus Xuezhikang 1.2g / d). Blood hs-CRP and IL-6 levels were measured before and after drug treatment. Results: (1) The hs-CRP and IL-6 levels in all EH patients were significantly higher than those in normal control group (P <0.05). (2) The hs- (P <0.05). (3) After treatment of Xuezhikang and routine treatment groups, the levels of hs-CRP and IL-6 were not significantly different (P> 0.05) (P <0.05). (4) The blood pressure of Xuezhikang group and conventional treatment group were significantly decreased (P <0.05) Compared with the two groups, Xuezhikang blood pressure decreased more significantly (P <0.05). Conclusion: The rise of inflammatory response index hs-CRP, IL-6 is closely related to the occurrence of EH complications. Xuezhikang can significantly reduce the levels of hs-CRP, IL-6 and blood pressure in patients with EH, suggesting that combined use of antihypertensive drugs and blood lipids Kang may be more beneficial for EH patients.